Related Experiment Video
Updated: Sep 24, 2025
11:23
Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
Published on: June 30, 2019
6.3K
Analysis of human Tribbles 2 (TRIB2) pseudokinase
John A Harris1, Emma Fairweather1, Dominic P Byrne1
1Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Methods in Enzymology
|May 7, 2022
Summary
Human Tribbles 2 (TRIB2) is a cancer-associated pseudokinase involved in cell survival and drug resistance. This study details lab procedures for purifying, stabilizing, and analyzing TRIB2, aiding the search for novel cancer therapeutics.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Human Tribbles 2 (TRIB2) is a pseudokinase implicated in cancer cell survival and drug resistance.
- Its precise physiological roles and therapeutic potential are not fully understood.
- TRIB2 interacts with key signaling modules like AKT, C/EBPα, and MAPK.
Purpose of the Study:
- To describe laboratory methods for the purification, stabilization, and analysis of human TRIB2.
- To outline screening procedures for identifying small molecule ligands targeting TRIB2.
- To facilitate further research into TRIB2 as a therapeutic target in cancer.
Main Methods:
- Purification of recombinant human TRIB2 protein.
- Stabilization techniques for pseudokinase analysis.
- Thermal shift assays for screening small molecule inhibitors.
- Analysis of TRIB2 interactions with E3 ubiquitin ligases.
Main Results:
- Established protocols for obtaining stable, purified human TRIB2.
- Demonstrated TRIB2's low affinity for ATP due to the absence of the DFG motif.
- Identified TRIB2 as a target for known small-molecule inhibitors.
- Characterized the regulatory role of the αC-helix and flanking region in TRIB2 stability.
Conclusions:
- Standardized laboratory procedures are crucial for studying TRIB2.
- TRIB2's unique structure presents opportunities for targeted drug development.
- Further investigation of TRIB2 ligands could lead to new cancer therapies.
